Mankind Pharma Limited (MANKIND.NS) fair value

ACCE thesis

Mankind Pharma is an Indian specialty and generic drugmaker whose domestic franchise is built around branded formulations sold through a large field force to doctors, with its best-known brands in cardiac, diabetes and women's health. A 70.8% gross margin and 20.6% operating margin reflect the branded, prescriber-driven model rather than commodity generics. Revenue grew 12.9% in the latest year, which is respectable for a company of this size but no longer the rapid expansion that justified its earlier multiple. At 46.0x trailing and 32.1x forward earnings the stock still carries a premium to most Indian pharma peers, so the thesis rests on whether margin durability and the growth in chronic-therapy volumes hold up. The name is worth a deeper look for the quality of its margins and the scale of the domestic franchise, and the valuation is the main reason to be cautious about entry.